Business Context and Reporting Period
This Form 6-K filing by Dr. Reddy's Laboratories Limited is dated July 23, 2026. The report serves to disclose a change in the Company's auditors, a requirement under the Indian Companies Act, 2013, which mandates the rotation of statutory auditors after a maximum permitted term.
Key Financial Metrics
This filing is a regulatory disclosure regarding auditor appointment and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Auditor Change: The Company is replacing Ernst & Young Associates LLP ("EY") with Deloitte Haskins & Sells, LLP ("Deloitte").
- Effective Date: Deloitte was approved by the Board of Directors on July 22, 2026, to serve as the Independent Registered Public Accounting Firm for the Company's Form 20-F and interim Form 6-K filings.
- Term: Deloitte will hold office for five consecutive years, from the conclusion of the 42nd Annual General Meeting until the conclusion of the 47th Annual General Meeting, subject to shareholder approval.
- Previous Auditor Status: EY completed the audit for the fiscal year ended March 31, 2026, and the interim review for the period ended June 30, 2026.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. Regarding risks and contingencies related to the auditor change:
- No Disagreements: There were no "disagreements" with EY on accounting principles, practices, financial statement disclosure, or auditing scope during the fiscal years ended March 31, 2026 and 2025, or the period from April 1, 2026, through the filing date.
- No Reportable Events: No "reportable events" as defined in Item 16F(a)(1)(v) of Form 20-F occurred during the relevant periods.
- Audit Opinions: EY's audit reports for the fiscal years ended March 31, 2026 and 2025, did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, scope, or accounting principles.
- Consultations: The Company did not consult Deloitte regarding accounting principles or potential audit opinions prior to their appointment.
Investor Verification Checklist
- Verify shareholder approval of Deloitte's appointment at the upcoming Annual General Meeting.
- Review the letter from EY (Exhibit 15.3) to confirm their agreement with the Company's statements regarding the lack of disagreements or reportable events.
- Monitor future Form 20-F filings to ensure the transition to Deloitte is reflected in the audit reports for the fiscal year ending March 31, 2027.